n/a (NVSEF)

: NVSEF · Precio en tiempo real · USD

n/a

n/a (n/a)

Al cierre: Invalid Date

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	n/a
Ingresos (TTM)	n/a
Beneficio neto (TTM)	n/a
Beta	n/a
EPS (TTM)	n/a
Ratio PER (TTM)	n/a
Adelante PE	n/a
P/B (TTM)	n/a
P/S (TTM)	n/a
Earnings Date	Oct 27, 2026

Precio de venta	n/a
Volumen	NaN
Volumen medio (20D)	n/a
Abierto	n/a
Anterior Cerrar	n/a
Rango del día	n/a - n/a
Rango de 52 semanas	n/a - n/a
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de NVSEF

A detailed description of the company is not yet available....

[Leer más]

Industria n/a

Sector n/a

IPO Fecha n/a

Empleados n/a

Bolsa de Valores n/a

Símbolo bursátil NVSEF

Perfil completo de la empresa

Próxima publicación de resultados

Está previsto que publique sus resultados el Oct 27, 2026, después del cierre del mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 día hace · MarketBeat

This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem

The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.

5 días hace · MT Newswires

Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent

(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.) Novartis

1 semana hace · 24/7 Wall St.

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is wh...

1 semana hace · 24/7 Wall St.

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose...

1 semana hace · GuruFocus.com

Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook

Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.

Página 1 de 2

n/a (NVSEF)

Acerca de NVSEF